

# GEORGIAN MEDICAL NEWS

ISSN 1512-0112

NO 2 (347) Февраль 2024

ТБИЛИСИ - NEW YORK



ЕЖЕМЕСЯЧНЫЙ НАУЧНЫЙ ЖУРНАЛ

Медицинские новости Грузии  
საქართველოს სამედიცინო სიახლენი

## GEORGIAN MEDICAL NEWS

Monthly Georgia-US joint scientific journal published both in electronic and paper formats of the Agency of Medical Information of the Georgian Association of Business Press.  
Published since 1994. Distributed in NIS, EU and USA.

**GMN: Georgian Medical News** is peer-reviewed, published monthly journal committed to promoting the science and art of medicine and the betterment of public health, published by the GMN Editorial Board since 1994. GMN carries original scientific articles on medicine, biology and pharmacy, which are of experimental, theoretical and practical character; publishes original research, reviews, commentaries, editorials, essays, medical news, and correspondence in English and Russian.

GMN is indexed in MEDLINE, SCOPUS, PubMed and VINITI Russian Academy of Sciences. The full text content is available through EBSCO databases.

**GMN: Медицинские новости Грузии** - ежемесячный рецензируемый научный журнал, издаётся Редакционной коллегией с 1994 года на русском и английском языках в целях поддержки медицинской науки и улучшения здравоохранения. В журнале публикуются оригинальные научные статьи в области медицины, биологии и фармации, статьи обзорного характера, научные сообщения, новости медицины и здравоохранения. Журнал индексируется в MEDLINE, отражён в базе данных SCOPUS, PubMed и ВИНТИ РАН. Полнотекстовые статьи журнала доступны через БД EBSCO.

**GMN: Georgian Medical News** – საქართველოს სამედიცინო სიახლენი – არის ყოველთვიური სამეცნიერო სამედიცინო რეცენზირებადი ჟურნალი, გამოიცემა 1994 წლიდან, წარმოადგენს სარედაქციო კოლეგიისა და აშშ-ის მეცნიერების, განათლების, ინდუსტრიის, ხელოვნებისა და ბუნებისმეტყველების საერთაშორისო აკადემიის ერთობლივ გამოცემას. GMN-ში რუსულ და ინგლისურ ენებზე ქვეყნდება ექსპერიმენტული, თეორიული და პრაქტიკული ხასიათის ორიგინალური სამეცნიერო სტატიები მედიცინის, ბიოლოგიისა და ფარმაციის სფეროში, მიმოხილვითი ხასიათის სტატიები.

ჟურნალი ინდექსირებულია MEDLINE-ის საერთაშორისო სისტემაში, ასახულია SCOPUS-ის, PubMed-ის და ВИНТИ РАН-ის მონაცემთა ბაზებში. სტატიების სრული ტექსტი ხელმისაწვდომია EBSCO-ს მონაცემთა ბაზებშიდან.

### WEBSITE

[www.geomednews.com](http://www.geomednews.com)

## К СВЕДЕНИЮ АВТОРОВ!

При направлении статьи в редакцию необходимо соблюдать следующие правила:

1. Статья должна быть представлена в двух экземплярах, на русском или английском языках, напечатанная через **полтора интервала на одной стороне стандартного листа с шириной левого поля в три сантиметра**. Используемый компьютерный шрифт для текста на русском и английском языках - **Times New Roman (Кириллица)**, для текста на грузинском языке следует использовать **AcadNusx**. Размер шрифта - **12**. К рукописи, напечатанной на компьютере, должен быть приложен CD со статьей.

2. Размер статьи должен быть не менее десяти и не более двадцати страниц машинописи, включая указатель литературы и резюме на английском, русском и грузинском языках.

3. В статье должны быть освещены актуальность данного материала, методы и результаты исследования и их обсуждение.

При представлении в печать научных экспериментальных работ авторы должны указывать вид и количество экспериментальных животных, применявшиеся методы обезболивания и усыпления (в ходе острых опытов).

4. К статье должны быть приложены краткое (на полстраницы) резюме на английском, русском и грузинском языках (включающее следующие разделы: цель исследования, материал и методы, результаты и заключение) и список ключевых слов (key words).

5. Таблицы необходимо представлять в печатной форме. Фотокопии не принимаются. **Все цифровые, итоговые и процентные данные в таблицах должны соответствовать таковым в тексте статьи**. Таблицы и графики должны быть озаглавлены.

6. Фотографии должны быть контрастными, фотокопии с рентгенограмм - в позитивном изображении. Рисунки, чертежи и диаграммы следует озаглавить, пронумеровать и вставить в соответствующее место текста **в tiff формате**.

В подписях к микрофотографиям следует указывать степень увеличения через окуляр или объектив и метод окраски или импрегнации срезов.

7. Фамилии отечественных авторов приводятся в оригинальной транскрипции.

8. При оформлении и направлении статей в журнал МНГ просим авторов соблюдать правила, изложенные в «Единых требованиях к рукописям, представляемым в биомедицинские журналы», принятых Международным комитетом редакторов медицинских журналов - <http://www.spinesurgery.ru/files/publish.pdf> и [http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html) В конце каждой оригинальной статьи приводится библиографический список. В список литературы включаются все материалы, на которые имеются ссылки в тексте. Список составляется в алфавитном порядке и нумеруется. Литературный источник приводится на языке оригинала. В списке литературы сначала приводятся работы, написанные знаками грузинского алфавита, затем кириллицей и латиницей. Ссылки на цитируемые работы в тексте статьи даются в квадратных скобках в виде номера, соответствующего номеру данной работы в списке литературы. Большинство цитированных источников должны быть за последние 5-7 лет.

9. Для получения права на публикацию статья должна иметь от руководителя работы или учреждения визу и сопроводительное отношение, написанные или напечатанные на бланке и заверенные подписью и печатью.

10. В конце статьи должны быть подписи всех авторов, полностью приведены их фамилии, имена и отчества, указаны служебный и домашний номера телефонов и адреса или иные координаты. Количество авторов (соавторов) не должно превышать пяти человек.

11. Редакция оставляет за собой право сокращать и исправлять статьи. Корректур авторам не высылаются, вся работа и сверка проводится по авторскому оригиналу.

12. Недопустимо направление в редакцию работ, представленных к печати в иных издательствах или опубликованных в других изданиях.

**При нарушении указанных правил статьи не рассматриваются.**

## REQUIREMENTS

Please note, materials submitted to the Editorial Office Staff are supposed to meet the following requirements:

1. Articles must be provided with a double copy, in English or Russian languages and typed or computer-printed on a single side of standard typing paper, with the left margin of 3 centimeters width, and 1.5 spacing between the lines, typeface - **Times New Roman (Cyrillic)**, print size - 12 (referring to Georgian and Russian materials). With computer-printed texts please enclose a CD carrying the same file titled with Latin symbols.

2. Size of the article, including index and resume in English, Russian and Georgian languages must be at least 10 pages and not exceed the limit of 20 pages of typed or computer-printed text.

3. Submitted material must include a coverage of a topical subject, research methods, results, and review.

Authors of the scientific-research works must indicate the number of experimental biological species drawn in, list the employed methods of anesthetization and soporific means used during acute tests.

4. Articles must have a short (half page) abstract in English, Russian and Georgian (including the following sections: aim of study, material and methods, results and conclusions) and a list of key words.

5. Tables must be presented in an original typed or computer-printed form, instead of a photocopied version. **Numbers, totals, percentile data on the tables must coincide with those in the texts of the articles.** Tables and graphs must be headed.

6. Photographs are required to be contrasted and must be submitted with doubles. Please number each photograph with a pencil on its back, indicate author's name, title of the article (short version), and mark out its top and bottom parts. Drawings must be accurate, drafts and diagrams drawn in Indian ink (or black ink). Photocopies of the X-ray photographs must be presented in a positive image in **tiff format**.

Accurately numbered subtitles for each illustration must be listed on a separate sheet of paper. In the subtitles for the microphotographs please indicate the ocular and objective lens magnification power, method of coloring or impregnation of the microscopic sections (preparations).

7. Please indicate last names, first and middle initials of the native authors, present names and initials of the foreign authors in the transcription of the original language, enclose in parenthesis corresponding number under which the author is listed in the reference materials.

8. Please follow guidance offered to authors by The International Committee of Medical Journal Editors guidance in its Uniform Requirements for Manuscripts Submitted to Biomedical Journals publication available online at: [http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html)  
[http://www.icmje.org/urm\\_full.pdf](http://www.icmje.org/urm_full.pdf)

In GMN style for each work cited in the text, a bibliographic reference is given, and this is located at the end of the article under the title "References". All references cited in the text must be listed. The list of references should be arranged alphabetically and then numbered. References are numbered in the text [numbers in square brackets] and in the reference list and numbers are repeated throughout the text as needed. The bibliographic description is given in the language of publication (citations in Georgian script are followed by Cyrillic and Latin).

9. To obtain the rights of publication articles must be accompanied by a visa from the project instructor or the establishment, where the work has been performed, and a reference letter, both written or typed on a special signed form, certified by a stamp or a seal.

10. Articles must be signed by all of the authors at the end, and they must be provided with a list of full names, office and home phone numbers and addresses or other non-office locations where the authors could be reached. The number of the authors (co-authors) must not exceed the limit of 5 people.

11. Editorial Staff reserves the rights to cut down in size and correct the articles. Proof-sheets are not sent out to the authors. The entire editorial and collation work is performed according to the author's original text.

12. Sending in the works that have already been assigned to the press by other Editorial Staffs or have been printed by other publishers is not permissible.

**Articles that Fail to Meet the Aforementioned  
Requirements are not Assigned to be Reviewed.**

## ავტორთა საქურაღებოლ!

რედაქციაში სტატიის წარმოდგენისას საჭიროა დაიცვათ შემდეგი წესები:

1. სტატია უნდა წარმოადგინოთ 2 ცალად, რუსულ ან ინგლისურ ენებზე დაბეჭდილი სტანდარტული ფურცლის 1 გვერდზე, 3 სმ სიგანის მარცხენა ველისა და სტრიქონებს შორის 1,5 ინტერვალის დაცვით. გამოყენებული კომპიუტერული შრიფტი რუსულ და ინგლისურენოვან ტექსტებში - **Times New Roman (Кириллица)**, ხოლო ქართულენოვან ტექსტში საჭიროა გამოვიყენოთ **AcadNusx**. შრიფტის ზომა – 12. სტატიას თან უნდა ახლდეს CD სტატიით.

2. სტატიის მოცულობა არ უნდა შეადგენდეს 10 გვერდზე ნაკლებს და 20 გვერდზე მეტს ლიტერატურის სიის და რეზიუმეების (ინგლისურ, რუსულ და ქართულ ენებზე) ჩათვლით.

3. სტატიაში საჭიროა გაშუქდეს: საკითხის აქტუალობა; კვლევის მიზანი; საკვლევი მასალა და გამოყენებული მეთოდები; მიღებული შედეგები და მათი განსჯა. ექსპერიმენტული ხასიათის სტატიების წარმოდგენისას ავტორებმა უნდა მიუთითონ საექსპერიმენტო ცხოველების სახეობა და რაოდენობა; გაუტკივარებისა და დაძინების მეთოდები (მწვავე ცდების პირობებში).

4. სტატიას თან უნდა ახლდეს რეზიუმე ინგლისურ, რუსულ და ქართულ ენებზე არანაკლებ ნახევარი გვერდის მოცულობისა (სათაურის, ავტორების, დაწესებულების მითითებით და უნდა შეიცავდეს შემდეგ განყოფილებებს: მიზანი, მასალა და მეთოდები, შედეგები და დასკვნები; ტექსტუალური ნაწილი არ უნდა იყოს 15 სტრიქონზე ნაკლები) და საკვანძო სიტყვების ჩამონათვალი (key words).

5. ცხრილები საჭიროა წარმოადგინოთ ნაბეჭდი სახით. ყველა ციფრული, შემაჯამებელი და პროცენტული მონაცემები უნდა შეესაბამებოდეს ტექსტში მოყვანილს.

6. ფოტოსურათები უნდა იყოს კონტრასტული; სურათები, ნახაზები, დიაგრამები - დასათაურებული, დანომრილი და სათანადო ადგილას ჩასმული. რენტგენოგრაფიების ფოტოასლები წარმოადგინეთ პოზიტიური გამოსახულებით **tiff** ფორმატში. მიკროფოტოსურათების წარწერებში საჭიროა მიუთითოთ ოკულარის ან ობიექტივის საშუალებით გადიდების ხარისხი, ანათალების შედეგის ან იმპრეგნაციის მეთოდი და აღნიშნოთ სურათის ზედა და ქვედა ნაწილები.

7. სამამულო ავტორების გვარები სტატიაში აღინიშნება ინიციალების თანდართვით, უცხოურისა – უცხოური ტრანსკრიპციით.

8. სტატიას თან უნდა ახლდეს ავტორის მიერ გამოყენებული სამამულო და უცხოური შრომების ბიბლიოგრაფიული სია (ბოლო 5-8 წლის სიღრმით). ანბანური წყობით წარმოდგენილ ბიბლიოგრაფიულ სიაში მიუთითეთ ჯერ სამამულო, შემდეგ უცხოელი ავტორები (გვარი, ინიციალები, სტატიის სათაური, ჟურნალის დასახელება, გამოცემის ადგილი, წელი, ჟურნალის №, პირველი და ბოლო გვერდები). მონოგრაფიის შემთხვევაში მიუთითეთ გამოცემის წელი, ადგილი და გვერდების საერთო რაოდენობა. ტექსტში კვადრატულ ფხიხლებში უნდა მიუთითოთ ავტორის შესაბამისი N ლიტერატურის სიის მიხედვით. მიზანშეწონილია, რომ ციტირებული წყაროების უმეტესი ნაწილი იყოს 5-6 წლის სიღრმის.

9. სტატიას თან უნდა ახლდეს: ა) დაწესებულების ან სამეცნიერო ხელმძღვანელის წარდგინება, დამოწმებული ხელმოწერითა და ბეჭდით; ბ) დარგის სპეციალისტის დამოწმებული რეცენზია, რომელშიც მითითებული იქნება საკითხის აქტუალობა, მასალის საკმაობა, მეთოდის სანდოობა, შედეგების სამეცნიერო-პრაქტიკული მნიშვნელობა.

10. სტატიის ბოლოს საჭიროა ყველა ავტორის ხელმოწერა, რომელთა რაოდენობა არ უნდა აღემატებოდეს 5-ს.

11. რედაქცია იტოვებს უფლებას შეასწოროს სტატია. ტექსტზე მუშაობა და შეჯერება ხდება საავტორო ორიგინალის მიხედვით.

12. დაუშვებელია რედაქციაში ისეთი სტატიის წარდგენა, რომელიც დასაბეჭდად წარდგენილი იყო სხვა რედაქციაში ან გამოქვეყნებული იყო სხვა გამოცემებში.

აღნიშნული წესების დარღვევის შემთხვევაში სტატიები არ განიხილება.

Yu-Ri Choi, Su-Bin Yu, Seoul-Hee Nam. ANTIBACTERIAL EFFECT OF CRATAEGUS PINNATIFIDA EXTRACT AGAINST ENTROCOCCUS FAECALIS A ROOT CANAL DISEASE-CAUSING BACTERIA.....	6-10
Larisa Melia, Revaz Sulukhia, Lali Pkhaladze, Nino Davidova, Archil Khomasuridze. MIFEPRISTON IN OBSTETRICS – WHY NOT?.....	11-14
Maryna Stoliarchuk. CORRELATION BETWEEN TRANSVERSE CEPHALOMETRIC PARAMETERS AND THE SEVERITY OF SKELETAL MALOCCLUSIONS.....	15-18
Deepak, Prashant Rao, Archana, Sowmya M, Sandeep. S, Suma S. A CROSS-SECTIONAL STUDY ON COVID-19 VACCINATION HESITATION AMONG UNIVERSITY STUDENTS.....	19-23
Tchernev G, Broshtilova V, Ivanov L, Alexandrov A, Smilov N, Kordeva S. DRUG RELATED NITROSOGENESIS, PHOTOCARCINOGENESIS AND ONCOPHARMACOGENESIS OF NODULAR MELANOMA: A CASE RELATED ANALYSIS CONCERNING THE POLYCONTAMINATION OF THE POLYMEDICATION WITH VALSARTAN/ HYDROCHLOROTHIAZIDE AND BISOPROLOL.....	24-27
Rawaa J. Matloob, Zeina A. Althanoon, Saad A. Algburi, Mudheher I. Salih, Marwan M. Merkhan. UPDATE ON THE USE OF METHOTREXATE IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS.....	28-33
Georgi Tchernev. (N-NITROSO) PROPAPFENONE INDUCED ADVANCED NODULAR MELANOMA-FIRST REPORTED CASE IN THE WORLD LITERATURE: THE INEXTRICABLE LINKS BETWEEN THE PHOTOCARCINOGENESIS, DRUG RELATED NITROSOGENESIS AND PHARMACO-ONCOGENESIS.....	34-37
Elham M. Mahmood, Entedhar R. Sarhat, Maryam T. Tawfeq, Siham A. Wadee. HISTOLOGICAL AND BIOCHEMICAL STUDY OF THE EFFECT OF FEXOFENADINE ON SALIVARY GLAND IN RATS.....	38-40
Valerii Vovk, Igor Duda, Alla Vovk. THE EFFECT OF A MULTIMODAL APPROACH ON THE RESULTS OF TREATMENT IN SURGERY: INTEGRATION OF CHEMOTHERAPY, SURGERY, AND RADIOTHERAPY.....	41-46
Haitham Alhussain, Deepak, Bharath Chandra V, Lakshmi. R, Sumana A, Jishamol KR. EXAMINATION OF THE INCIDENCE OF POOR SLEEP QUALITY AND FACTORS ASSOCIATED FOR POOR SLEEP DURING THE VARIOUS PHASES OF PREGNANCIES.....	47-53
N. Ksajikyan, H. Aghababyan, M. Sargsyan. ASSESSMENT OF REACTIVITY TO THE BODY UNDER CONDITIONS OF PHYSICAL ACTIVITY IN STUDENTS AGED 17-20 YEARS....	54-58
Abinaya Srinivasa Rangan, Dhanush Balaji.S, Utham Chand, Raghunathan E.G, Deepthi.N, Prasanna Karthik.S. TRIGLYCERIDE – GLUCOSE INDEX, REMNANT CHOLESTEROL AND COMMON CAROTID ARTERY INTIMA-MEDIA THICKNESS AS AN ATHEROSCLEROTIC MARKER IN ISCHEMIC STROKE PATIENTS.....	59-65
Riyam AH. Al-Barwani, Entedar R. sarhat. BREAST CANCER-MODULATED OMENTIN AND VASPIN PLASMA LEVELS.....	66-69
Tchernev G, Dimova D. PERIOULAR HIGH RISK BCCS AFTER ADDITIONAL/PARALLEL INTAKE OF TORASEMIDE, MOXONIDINE AND MIRABEGRON: IMPORTANT LINKS TO SKIN CANCER RELATED (PHOTO-) NITROSOGENESIS IN THE CONTEXT OF PHARMACO-ONCOGENESIS.....	70-76
Abinaya Srinivasa Rangan, Dhanush Balaji.S, Saranya.C, Raghunathan E.G, Deepthi.N, Prasanna Karthik.S. ASSOCIATION OF MPV AND RDW WITH DISEASE ACTIVITY IN PATIENT WITH RHEUMATOID ARTHRITIS.....	77-81
Julieta Nino Gulua, Lela Sturua, Maia Khubua, Lela Shengelia. THYROID CANCER AS A PUBLIC HEALTH CHALLENGE IN GEORGIA.....	82-86
Rahma S. Almallah, Hani M. Almkhtar. MIRABEGRON INDUCED RELAXATION OF ISOLATED BOVINE CORONARY SEGMENTS: ROLE OF NO AND K+ CHANNEL.....	87-92
Gogotishvili Mariam, Gogebashvili Nino, Bakradze Mzia, Gorgiladze Tinatin, Japaridze Fridon. MANIFESTATIONS OF DISEASES OF THE ORAL MUCOSA OF PATIENTS IN THE ADJARA REGION DURING THE COVID-19 PANDEMIC.....	93-95
Nithesh Babu R, Fathima S Nilofar, Saranya Palanisamy, Gnanadeepan T, Mahendra Kumar K. EXPLORING THE INCIDENCE AND PREVALENCE OF NEW-ONSET AUTOIMMUNE DISEASE FOLLOWING COVID-19 PANDEMIC: A SYSTEMATIC REVIEW.....	96-103

E. Mosidze, A. Chikovani, M. Giorgobiani. ADVANCES IN MINIMALLY INVASIVE SURGERY FOR PECTUS EXCAVATUM: ENHANCING OUTCOMES AND PATIENT CARE.....	104-107
Nithesh Babu R, Fathima S Nilofar, Saranya Palanisamy, Gnanadeepan T, Mahendra Kumar K. SIGNIFICANCE OF NEUTROPHIL-LYMPHOCYTE RATIO AND PLATELETLYMPHOCYTE RATIO AS PROGNOSTIC MARKERS OF DISEASE SEVERITY IN SYSTEMIC LUPUS ERYTHEMATOSUS.....	108-112
Athraa E. Ahmed, Nibras H. Hameed. PREVALENCE OF FETAL CONGENITAL ANOMALIES IN PATIENTS ATTENDING TIKRIT TEACHING HOSPITAL.....	113-116
Kazantcev A.D, Kazantceva E.P, Sarkisyan I.P, Avakova A.E, Shumakova A.O, Dyachenko Y.E, Mezhenko D.V, Kustov Y.O, Makarov Daniil Andreevich, Guliev M.T, Babaeva M.M. COMPARATIVE ANALYSIS OF POSITIVE AND NEGATIVE EXPECTATIONS WITH CONTROL OF VOLITIONAL EFFORT IN YOUNG AND OLD AGES AS RISK FACTORS OF SOCIAL AGING.....	117-121
Arnab Sain, Sarah Arif, Hoosai Manyar, Nauman Manzoor, Kanishka Wattage, Michele Halasa, Arsany Metry, Jack Song Chia, Emily Prendergast, Ahmed Elkilany, Odiamehi Aisabokhale, Fahad Hussain, Zain Sohail. CURRENT CONCEPTS IN THE MANAGEMENT OF BOXER'S FRACTURE.....	122-124
Gonashvili Meri, Kilasonia Besarion, Chikhladze Ramaz, Merabishvili Gela, Beriashvili Rusudan. MEDICO-LEGAL APPLICATIONS OF FRACTURE HEMATOMA: REVIEW.....	125-130
Zynab J. Jarjees, Entedhar R. Sarhat. ASSESSMENT OF OSTEOPONTIN, SCLEROSTIN, AND OSTEOCALCIN LEVELS IN PATIENTS WITH HYPOTHYROIDISM ON MEDICAL THERAPY.....	131-135
Tchernev G, Dimova D. EDUCATION FROM DERMATOLOGISTS: THE SIMULTANEOUSLY DEVELOPMENT OF 16 KERATINOCYTIC CANCERS AFTER USE OF METFORMIN IN COMBINATION WITH LOSARTAN/ HYDROCHLOROTHIAZIDE, METOPROLOL AND NIFEDIPINE-IMPORTANT LINKS TO DRUG RELATED (PHOTO)-NITROSO-CARCINOGENESIS AND ONCOPHARMACOGENESIS.....	136-141
Ismayilov M.U, Polukhov R.Sh, Poddubny I.V, Magammedov V.A. COMPARATIVE ASSESSMENT OF SURGICAL TREATMENT OF COMPLICATIONS OF ULCERATIVE COLITIS IN CHILDREN.....	142-148
Arnab Sain, Arsany Metry, Nauman Manzoor, Kanishka Wattage, Ahmed Elkilany, Michele Halasa, Jack Song Chia, Sarah Arif, Fahad Hussain, Odiamehi Aisabokhale, Zain Sohail. THE ROLE OF DISTAL LOCKING IN INTRAMEDULLARY NAILS FOR HIP FRACTURE FIXATION: A REVIEW OF CURRENT LITERATURE.....	149-150
Buba Chachkhiani, Manana Kalandadze, Shalva Parulava, Vladimer Margvelashvili. EFFECT OF SURFACE ABRASION AND TEMPERATURE TREATMENT ON METASTABLE TETRAGONAL ZIRCONIUM DIOXIDE (EXPERIMENTAL STUDY).....	151-155
Abdulrahman A Abdulhamed, Luma W Khaleel. CARDIOPROTECTIVE EFFECT OF GLYCYRRHIZA GLABRA EXTRACT AND GLYCYRRHIZA GLABRA SILVER NANOPARTICLE AGAINST ALLOXAN AND NICOTINAMIDE INDUCED DIABETIC CARDIAC INJURY IN RATS.....	156-159
Larysa Pentiuk, Tetiana Niushko, Emiliia Osiadla. FEATURES OF BLOOD PRESSURE DAILY MONITORING INDICATORS, STRUCTURAL AND FUNCTIONAL CHANGES OF THE LEFT VENTRICLE AND VESSELS IN WOMEN WITH HYPERTENSION II STAGE OF DIFFERENT REPRODUCTIVE AGE AND THEIR RELATIONSHIP WITH SEX HORMONES LEVEL.....	160-167
Rana dawood Salman Al-kamil, Thamir F. Alkhiat, H. N. K. AL-Saman, H. H. Hussein, Dawood Chalooob Hilyail, Falah Hassan Shari. THE EFFECT OF NUTRITIONAL GENOMICS ON CARDIOVASCULAR SYSTEM.....	168-176
Sopiko Kvaratsthelia. PREVALENCE OF DENTITION, DENTAL ARCHES AND DENTAL ANOMALIES.....	177-180
Dorosh D, Liadova T, Popov M, Volobuieva O, Pavlikova K, Tsivenko O, Chernuskiy V, Hrek I, Kushnir V, Volobuiev D. THE EFFECT OF MELATONIN ON THE SERUM LEVEL OF INTERLEUKIN 31 IN HERPESVIRUS SKIN DISEASES ON THE BACKGROUND OF HIV.....	181-184

## THE EFFECT OF NUTRITIONAL GENOMICS ON CARDIOVASCULAR SYSTEM

Rana dawood Salman Al-kamil<sup>1</sup>, Thamir F. Alkhiat<sup>2</sup>, H. N. K. AL-Saman<sup>3</sup>, H. H. Hussein<sup>4</sup>, Dawood Chaloob Hilyail<sup>5</sup>, Falah Hassan Shari<sup>6</sup>.

<sup>1,5</sup>Department Of Clinical and laboratory science, College of Pharmacy, University of Basrah, Iraq.

<sup>2</sup>Department of surgery, Al-Sader Teaching Hospital, Basrah Medical college, University of Basrah, Iraq.

<sup>3,4</sup>Department of Pharmaceutical Chemistry, College of Pharmacy, University of Basrah, Iraq.

<sup>6</sup>Almaaaqal University College of Pharmacy, Basrah, Iraq.

### Abstract.

The idea that obesity and cardiovascular diseases together are considered for a sizable share of adult global morbidity and mortality is supported by epidemiological data. They have intricate systems in which environmental and genetic variables interact, including nutrition. As an environmental component, nutrition has a major and well-known role in managing health and preventing obesity and disorders connected to obesity, such as cardiovascular disease (CVD). Nonetheless, people with the same food pattern but obese exhibit a notable difference in CVD. This variance might be explained by the various genetic polymorphisms which gave rise to the field of nutrigenetics. The discipline known as nutritional genomics, or nutrigenetics, examines and describes gene variants linked to varying reactions to particular nutrients and links these variations to various disorders, including obesity-related cardiovascular disease (CVD). Therefore, tailored nutrition advice depending on a person's genetic background could enhance the results of a particular dietary intervention and offer a novel dietary technique to enhance health by lowering obesity and cardiovascular disease. With these suppositions, it seems reasonable to assume that understanding food and gene interactions will provide more targeted and efficacious dietary treatments in preventing obesity and CVD by nutrigenetics-based personalized nutrition. In addition to elucidating the connection between diet and gene expression and the major nutrition-related genes involved in obesity and CVD, this research seeks to provide a concise summary of the greater significant genes linked to obesity and CVD.

**Key words.** Nutrigenomics, cardiovascular disease nutrients, genetics, genomics, precision nutrition.

### Introduction.

The study of how particular meals interact with particular genes, which raises the danger of chronic disease such as obesity and heart disease and may also cause some types of cancer, is known as the science of the effect of nutrition on genes. This helps us understand the negative and positive impact of food on our vital systems before disease occurs. Its first breakthrough was when humans discovered the genetic map in the year 2000 [1]. We know four disorders-oxidation, metabolic processes, inflammation, or psychological stress-cause most diseases. The goal of studying nutrition's impact on genes is to comprehend how food affects the first three imbalances. It also clarifies how a person's genetic composition influences how food affects their health. It is crucial to understand this effect because

chronic diseases are not caused by a single genetic mutation but rather by intricate interactions between multiple genes. This requires a great degree of control over the types of genes and environmental conditions, making the research on the relationship between diet and genes more complex and difficult to predict. Recently, Numerous studies demonstrated how nutrients alter gene expression through protein synthesis, signal transduction, gene regulation, and other processes and that not everyone benefits from them similarly. Understanding how diet influences genetics has created a window of opportunity for tailored recommendations that lessen the influence of dietary-related risk factors for disease. Though "personalized nutrition," or a diet tailored to an individual's genes, is still relatively new, it is anticipated that genes will significantly influence an individual's daily dietary needs. Finding the genes that cause or are a causative factor for chronic diseases and determining the nutrients that directly affect these genes' activity while accounting for environmental factors around them are some of the challenges that research on the impact of nutrition on genes must overcome [2-5].

Coronary Cardiovascular disease is considered the most common cardiovascular disease and is closely related to the type and quantity of food. It is also hereditary and results from the accumulation of cholesterol and fats in the walls of the arteries and its formation begins Childhood when food is saturated with fat. It has causes called danger factors, like high diabetes, Blood cholesterol, smoking, age, genetics, high blood pressure, etc., Falling under the influence of stress and psychological pressure [6].

The field of nutrigenomics seeks to understand how nutrition influences metabolism and cellular function through histone modification and DNA methylation, two epigenetic processes that alter gene expression. The eicosanoid Biosynthesis insight focuses on the most recent findings about the nutrigenomics of carbs and fats to provide insight into how gene interactions and food components affect an individual's phenotype [7,8].

Recent research has provided substantial evidence of the impact of gene-diet interactions on CVD biomarkers, as well as the onset and course of the disease. Age groups and populations have shown consistent results regarding the cardiovascular implications of gene-nutrient interactions with respect to macronutrients and genes. On the other hand, the impacts of certain genes on gene-nutrient interactions have only been observed in particular age groups, genders, or populations, and they require further investigation and verification [9,10].

Heart disease is a group of illnesses that includes the following diseases: deep vein thrombosis, pulmonary embolism, peripheral



arterial, coronary heart, rheumatic heart, and cerebrovascular. With almost one-third of all deaths coming from CVD, it is the main cause of death worldwide. The USA is not far behind other low- and middle-income nations, where almost three-quarters of deaths occur. In the US, cardiovascular disease is the cause of one in four fatalities. Genetic factors largely influence cardiovascular illnesses, but there is also strong evidence linking nutrition and lifestyle variables—such as obesity and sedentary behavior—to the onset, progression, and risk factors of CVD. It is also well recognized that a person's nutrition and lifestyle choices throughout their early years can impact their later-life risk of illness. People have long been fascinated by the differences in CVD susceptibility among genotypes, ethnicities, and environments. Recently, there has been a surge of curiosity regarding the impact of individual genetic variation on how human populations respond to nutrition. Additionally, there is a growing understanding that combining genes and environment, such as diet and nutrition, can significantly influence metabolic changes. Thus, one of the most important aspects of controlling CVD is comprehending the basic mechanisms behind the disease and putting this information to use [11-15].

Finding genetic variants that affect the risk of CVD due to food may help guide future research on nutritional interventions. Even though a wealth of scientific data shows that nutrition can alter a person's hereditary vulnerability to cardiovascular disease, diet recommendations are still difficult to implement based on this knowledge. Therefore, Better methods are required to obtain accuracy in gathering dietary data and to simplify computational methods for significant and successful nutritional treatments [16].

Researching the impacts of dietary patterns and specific nutrients has attracted much interest. Many dietary strategies, such as Mediterranean, Prudent, and Dietary Approaches to Stop Hypertension (DASH), are good for cardiovascular health. They all stress the health benefits of fruits, vegetables, and whole grains and the negative consequences of sweets, saturated fats, and sodium. The trial is a well-known study that illustrates the advantages of the Mediterranean diet. The PREDIMED experiment aimed to ascertain how different types of fat affected the mortality rate from CVD. High-risk Spanish adults for cardiovascular reasons are following a low-fat or Mediterranean diet supplemented with almonds or olive oil. Providing nuts or olive oil along with instructions was the foundation of the intervention. The rate of significant CV events served as the main outcome. According to Ortega-Azorin and colleagues, a low Mediterranean diet was associated with a higher relationship between FTO-rs9939609 MC4R-rs17782313 and T2D [17-19]. Several PREDIMED trial studies have shown how well a Mediterranean diet can modulate the genetic associations that lead to diabetes, obesity, and other cardiovascular disease risk factors. A multi-center study, Dietary Approaches to Stop Hypertension (DASH), examined how healthy eating habits could affect hypertension. An analysis of genotype differences in the angiotensinogen, beta2-adrenergic receptor, and kallikrein loci revealed differences in the effects of sodium intake on blood pressure between persons following the Western diet and the DASH diet. Furthermore, the combination of low-fat and hypocaloric diets interacts with

BDNF SNPs and circadian locomotor cycles kaput (CLOCK) to influence phenotypes related to obesity, inflammation, and diabetes (Table 1) [20].

#### **The relationship of some foods to diseases.**

In countries with good statistical coverage, it was found that in more than 30% of cases, food contributes to diseases such as cancers and other physiological diseases, including atherosclerosis, obesity, high blood pressure, and diabetes (especially type 2). There are also a number of diseases that were known in the past and were treated by modifying food intake, such as scurvy, which results from a deficiency of vitamin C and has its well-known characteristics and symptoms, and its severity increases when it occurs in early childhood, represented by a disturbance in the growth of muscles and connective tissues. It was possible to get rid of this defect by increasing the intake of foods containing On vitamin C or using pharmaceutical preparations, as well as beriberi disease resulting from a deficiency (vitamin B1) Thiamine, which leads to symptoms mainly concentrated in dysfunction of the nervous system, heart disease, etc., as well as rickets resulting from a deficiency of vitamin D, which can be inherited and passed on to generations. The next in addition to other diseases, the most important of which are chronic conditions, some of which can be summarized in (Table 2) [21].

#### **Obesity and cardiovascular diseases (CVDs).**

The extensive deterioration of cardiovascular physiology resulting from structural and functional changes generated by obesity is one of the most significant effects of obesity. Due to increased blood volume, cardiac output, stroke volume, and heart rate, these adaptive mechanisms translate into significant hemodynamic changes that lead to progressive cardiac remodeling, including left atrial enlargement, left ventricular (LV) dilation, and eccentric or concentric LV hypertrophy. The effects of extra adipose tissue on the body have been well-documented. These effects include the synthesis and release of hormones and cytokines. Adipokines are among the latter, and they play a key role in several pathways leading to chronic low-grade inflammation formation. This inflammation raises the danger of developing heart disease (HD) because of its proatherogenic action. The accumulation of extra adipose tissue increases the deposition of epicardial adipose tissue (EAT), which is known as a critical factor in developing obesity-related cardiovascular problems. A local proatherogenic impact caused by elevated EAT raises the risk of arrhythmias, such as atrial fibrillation and coronary heart disease. Changes in the gut microbiota brought on by obesity set off several inflammatory cascades that raise the risk of cardiometabolic events and the generation of metabolites linked to cardiovascular risk. The microbiota-derived metabolite trimethylamine N-oxide, identified as a predictive marker for obesity-related cardiovascular events beyond conventional danger factors, has come to light due to emerging evidence. Specifically, research has shown that TMAO increases the danger of heart failure, stroke, and atherosclerosis. A recent study found that TMAO serum levels positively correlated with the Fatty Liver Index and the Visceral Adiposity Index, serving as a gender-specific predictor of non-alcoholic fatty liver problems and an indicator of adipose dysfunction, respectively [22-25].

## Results and discussion

**Table 1.** Gene by nutrition interaction impacts on CVD biomarkers that are consistent (replicated).

Gene	SNP	Nutrient/diet	CVD outcome	Discussion
ACE	rs4343	Blood pressure	-	Compared to AA or AG carriers, GG carriers exhibited greater systolic blood pressure.
ACE	INDEL	Hypertension	-	In ID/DD genotype but not II genotype, a higher salt intake was associated with an increase in hypertension.
CLOCK	rs4580704	Mediterranean diet	Type 2 diabetes status	After approximately five years of intervention, G carriers had a lower risk of type 2 diabetes than CC genotypes.
CLOCK	rs4580704	Low fat diet	C-reactive protein	After a 12-month intervention, CC carriers had a higher reduction in hs-CRP than CG or GG carriers.
CLOCK	rs1801260	Low fat diet	Insulin concentrations	After a year of intervention, TT carriers showed greater insulin sensitivity, lower plasma insulin, and HOMAIR than C carriers.
CLOCK	rs3749474	Hypocaloric diet	BMI	When dietary fat rose, T carriers' BMI increased, but following a 84 days calorie restriction program, CC carriers' BMI did not alter.
FTO	rs8050136	Carbohydrate intake	Obesity	In a cross-sectional study of Asian Indians, carriers of A had a higher risk of obesity than carriers of CC.
FTO	rs9939609	High protein intake	BMI	In children who consumed more protein, there was a larger correlation between BMI and rs9939609.
FTO	rs1558902	Protein intake	BMI	AA carriers who consumed less protein than TT carriers did so at a greater BMI.
FTO	rs9939609	Protein intake	BMI	When comparing the low-protein consumption group to the high-protein intake group, the association between rs9939609 and BMI was less pronounced.
FTO	rs9939609	Dietary saturated fat intake	Obesity	Compared to TT carriers, A carriers had a greater risk of obesity that was increased by a high intake of saturated fat in the diet during the course of a 7.5-year longitudinal study.
FTO	rs9939609	Energy-adjusted fat intake	BMI	In the high-fat diet group, but not in the low-fat diet group, carriers had greater BMI consumption.
FTO	rs1558902	Fried food consumption	BMI	Compared to low or normal fried food users, there was a higher correlation between the FTO variant and BMI in high fried food consumers.
BDNF	rs4923461	High protein intake	BMI	Compared to GG carriers, A carriers had a higher BMI and consumed more protein.
BDNF	rs10767664	Hypocaloric diet	BMI	After 90 days intervention, obese participants with AA carriers exhibited a higher reduction in BMI than those with T carriers.
FADS1	rs174547	Linoleic acid (LA) intake	BMI	Instead of the high LA intake group, each copy of the minor allele was linked to a reduced waist circumference and BMI in the lower LA intake group
FADS1	rs174547	Polyunsaturated fat (PUFA) intake	LDLc	In a cross-sectional investigation, C carriers compared to TT carriers showed reduced LD values only in the lowest tertile of n-3 PUFA intakes.

*BDNF*, or brain-derived neurotrophic factor; *ACE*, or angiotensin-converting enzyme; *Kaput* is cycled by the *CLOCK* Circadian Locomotor Output; *FTO* Fat mass and obesity-associated BMI Body mass index; *FADS1* fatty acid desaturase 1; Lower-density lipoprotein cholesterol, or *LDLc*.

**Table 2.** The relationship of some foods to diseases.

Food type	Diseases			
	Cancers	Arteriosclerosis	Obesity	diabetic
Foods rich in calories	+	+	+	+
Foods rich in saturated fats	+	+	+	+
High salty foods	+ **	+	...	+
Foods poor in fiber and complex carbohydrates	+	+	...	+
Foods poor in antioxidants	+	+	...	+

+ Having a huge impact.

\*\* Helped by the presence of other foods.

...No effect detected.

### Nutrition Aspects of prohibition in cases of fatness.

Research conducted on the matter has shown that nutrition and lifestyle significantly impact CVD risk. This is why public health programs to lower the risk of CVD have focused on dietary guidelines. Despite that effort, the anticipated decrease in CVD mortality only sometimes materializes. This failure is marked as a genetic variation and individual variability in

response to dietary recommendations and potentially to the reciprocal interactions between both factors [26-28].

The Human Genome Project identified numerous genes and the proteins that result from them as potentially contributing to these variations in how differently people respond to nutrition. The field of study known as "nutrigenetics" examines how genetic variability controls how differently each person reacts

to a given diet. It can be viewed as a subset of nutrigenomics, which more broadly studies how foods interact with the genome while accounting for genetics, epigenetics, and variations in gene expression. Advances in nutrigenomics and nutrigenetics have made it possible to use tailored nutrition to prevent serious illnesses like cardiovascular disease (CVD). According to epidemiologic studies, individual genetics play a major role in the significant tendency to CVD. Several twin and familial investigations and extensive long-term cardiovascular cohort studies validated this idea. Numerous genes or loci linked to atherosclerosis were found by GWAS; other studies have validated several of these findings [29,30].

Nevertheless, the found susceptibility alleles could only account for approximately 30% of the predicted heritability variance. Several limitations of genetics research have been proposed as contributing to the missing heritability, including the failure to take gene–gene interactions into account, the study power being inadequate to identify rare variants, and the role of environmental factors, such as dietary habits, among others. With these suppositions, it makes sense that clarifying gene–diet connections will facilitate more targeted and efficient tailored nutrition therapies for CVD prevention. Cardiovascular events may be avoided by adopting nutrigenetics, which focuses on genetic variations that can explain differences in how different nutrients and dietary treatments affect an individual. As was previously indicated, several studies demonstrated that, depending on the many dietary components contained, there is a significant variation in response to dietary intervention. Molecular genetics was investigated as soon as it was discovered as a tool capable of explaining this variability. However, dietary reference values—like recommended dietary allowances are created assuming that the various metabolic outcomes resulting from nutrient intake follow a Gaussian distribution and are intended for the whole population. Because population subgroups have different genetic makeups, these reference values may not be optimum for them. For example, there may be considerable differences in transferring the proteins for a given vitamin or in the activity of enzymes needed to metabolize that micronutrient or require it as a cofactor. While a single SNP might not have much impact compared to other established risk factors (like a family history of CVDs), several tiny genetic variations linked to different environmental exposures (like an unsatisfactory diet) may cause significant alterations in gene expression. The interactions between these variables may significantly alter the final phenotype or, conversely, may be in danger due to the co-existence of these adverse circumstances. This context may be especially concerning when it comes to pathways that may encourage atherogenesis (i.e., inflammation and lipid metabolisms) in individuals with high cardiovascular disease risk, such as obese people [31-35].

In the early years of this field, most nutrigenetic studies were observational; however, in the last few years, there has been a notable surge in the number of interventional studies, including genetic variability for dietary responsiveness. This is significant since one of the most common criticisms against nutrigenetics and nutrigenomics by skeptics was that observational rather than interventional research was used to derive treatment recommendations based on molecular nutrition. In this regard,

new data from nutrigenetics-based interventional research has shown some pathways that may be responsible for a variety of dietary responses and, as a result, may either cause or prevent CVD in patients who are at risk [36].

#### **Genetic variations influencing a patient's response to a nutritional intervention designed to lower their risk of cardiovascular disease.**

The genetic contributions to pathways that should be taken into account when creating individualized dietary recommendations to prevent cardiovascular disease in obese people are described in the paragraph that follows. Here, we present new data that supports the link between certain food intake responsiveness and genetic variations. To find uses for nutrigenetics in clinical practice, we specifically concentrated on observational research and clinical trials (summarized in Table 1) examining the impact of nutrient supplementation on cardiovascular outcomes. Figure 1 [20], reports a graphic representation of individualized therapies designed to lower the risk of cardiovascular disease (CVD) in obese patients based on how well they respond to particular nutrients or dietary regimens.


Graphical depiction of individualized interventions designed to lower the risk of cardiovascular disease (CVD) in obese patients based on how well they respond to particular nutrients or diets. In obese patients, a customized diet based on nutrigenomics can prevent cardiovascular disease by improving lipid profiles and reducing inflammation [37].

#### **Folate.**


Micronutrient abundance and shortage are well known to affect the stability of the genome, which in turn affects nutrient and gene–nutrient interactions (which are impacted by genotype). SNPs can affect the level of micronutrients and their associated metabolic disorders. Consequently, by controlling these interactions, (micro)nutrients may raise or lower the likelihood that a disease would manifest [38].

The control of homocysteine levels through folate intake is a key example. An integrated indicator of one-carbon metabolism, plasma homocysteine is positively connected with alcohol intake and negatively correlated with folate, vitamin B6, and vitamin B12 intake. One indicator of the risk of CVD is the build-up of homocysteine. Inflammation is one of the many pathways that have been proposed to encourage the beginning of CVD. The estimated heritability of plasma homocysteine is 8–57%. Among the most studied variants linked to elevated plasma homocysteine is the 5,10 MTHFR gene's C677T polymorphism (rs1801133). Because carriers of the T allele have a decreased capacity to convert methylenetetrahydrofolate to methyltetrahydrofolate, the one-carbon cycle pathway's homeostasis is compromised. According to a recent meta-analysis, the TT genotype has been linked to reduced blood folate levels, higher plasma homocysteine levels, and a decreased response to short-term folate supplementation. These findings reinforce the necessity of identifying MTHFR TT carriers to minimize negative consequences and guarantee that sufficient folate consumption can overcome genetic factors that may raise the risk of developing CVD. It has been shown that the MTHFR genotype affects how well hyperhomocysteinemia is treated with folate supplementation [39,40].

## PERSONALIZED INTAKE OF



**Figure 1.** Nutrition tailored by nutrigenetics for obesity and cardiovascular disorders. Graphical depiction of individualized interventions designed to lower the risk of cardiovascular disease (CVD) in obese patients based on how well they respond to particular nutrients or diets. In obese patients, a customized diet based on nutrigenomics can prevent cardiovascular disease by improving lipid profiles and reducing inflammation[37].



**Figure 2.** Results of OMICs and their impact on nutritional studies.

### Carbohydrate nutrition and its genetic effects.

Feeding a high-energy diet causes obesity and metabolic syndrome to develop early in life, perhaps because the body is unable to handle the meal's high energy density. Type 2 Diabetes, Obesity, and Energy Balance. In this situation, glucose is the ideal illustration of how organisms can adapt to varying dietary availability. Mammals have a complex response to dietary glucose because it involves changes in hormone production that are dependent on glucose and impact glucose metabolism, such as stimulating insulin secretion and inhibiting

glucagon release. It was previously believed that glucagon and insulin were the primary up-and-down transcriptional regulators of macronutrient metabolism (Figure 2) [21].

This conventional perspective is superseded by the novel idea that glucose produces signals in cells. In addition to influencing the expression of the  $\beta$ -cell gene in the pancreas, glucose also affects other areas of the human body, encouraging bloodstream absorption, intracellular metabolism, and fat absorption. Glucose in adipose tissue and liver induces the transcription of glycolytic and lipogenic enzymes. Furthermore, when insulin is

present, glucose represses genes that encode for gluconeogenic pathway enzymes [41,42].

Notably, the activity of glucokinase, which initiates glucose signaling, is necessary for the liver's effective glucose-mediated control of gene transcription. Several transcription factors must be activated and induced for glucose transcriptional activity to occur. These transcription factors can all be efficiently upregulated by high-carb diets. Most of the elements that have been studied are the carbohydrate activity element-binding protein (ChREBP), which interacts with Mlx after a heterodimerization and binding procedure to the carbohydrate activity element (ChoRE) stimulating genes that are regulated by glucose, and are involved in fat synthesis, fructose degradation, and glycolysis. Colon, muscle, liver, pancreas, and adipose tissue contain high percentages of ChREBP containing a basic helix-loop/leucine loop (bHLH/ZIP) DNA-binding domain, its extensions are proline-rich, its ZIP-like domain, and its nuclear localization signal is repressed by Ser196 phosphorylation as well as by Protein kinase (PK), and that the activation process is two-step and includes dephosphorylation of some residues involved in the first mechanism, and glucose is regulated through ChREBP. (Figures 2 and 3) [21]. This second one, however, is triggered by two regulatory domains and entails a dynamic intramolecular inhibition. A high-carb diet causes mRNA levels to rise, whereas a high-fat diet does not cause them to do so. Fasting and feeding conditions control liver ChREBP expression and activity. As a result of Thr666 in the DNA-binding domain being dephosphorylated, feeding causes ChREBP to translocate to the nucleus and activate ChREBP. A halt signal is represented by enhanced lipogenesis because it triggers AMP-activated. Stimulating lipogenesis is a stop signal because it triggers AMP-activated protein kinase (AMPK), which phosphorylates Ser568 to block ChREBP DNA-binding ability (Figure 3) [21]. In hepatic cells, the regulation of glycolytic and lipogenic genes is glucose dependent. The red-colored enzymes are those whose gene transcription is elevated in response to glucose. For more information, see the text. Rather, they demonstrated the critical role of glucose-6-phosphate (G6P) in ChREBP activation through an allosteric conformational shift that permits Mlx recruitment. Furthermore, they revealed that fructose 2,6-bisphosphate (F2,6BP) is

necessary for the transcription of genes controlled by glucose in the liver; specifically, F2,6BP facilitates the recruitment of ChREBP to the promoter of target genes, such as the one encoding glucose-6-phosphatase. A concept like this does not rule out the possibility of other metabolites operating in tandem or at downstream locations. Evidence suggests that ChREBP is also involved in converting carbohydrates to lipids. For example, the livers of ChREBP/mice have lower levels of glycogen and triglycerides than those of their wild-type littermates; in obese mice, ChREBP knockdown improves insulin resistance, glucose intolerance, and liver steatosis; and in diabetic livers, ChREBP is significantly upregulated, as well as in models of hyperphagia, such as ob/ob mice [43-44].

Obese persons have higher levels of the hormone FGF-21 than lean subjects. Starvation can also produce FGF-21 through the peroxisome proliferator-activated receptor (PPAR) $\alpha$ . As sucrose, fructose, and glucose are also ingested, studies have linked the intake of high-sucrose diets to specific cancer onsets [45]. The mechanisms behind these effects include the expression of at least 109 genes (related to cell adhesion, metabolic pathways, cell cycle regulation, and transduction signaling) being modulated in a sucrose-dependent manner. Specifically, high-sucrose supplementation modifies genes implicated in IGF-I signaling, indicating a role for this pathway in intestinal cell proliferation dependent on high-sucrose consumption.


#### Lipids' Effects on Gene Expression.

Fatty acids, cholesterol, and liposoluble vitamins are examples of dietary lipids essential for healthy growth, development, and wellbeing maintenance. Similar to how dietary fats and carbohydrates affect gene expression, they do so due to a conflict with our slowly evolving genome, which is linked to several "typically Western" disorders [46].


#### The relationship of diet to genetic change in humans.

Epidemiological research has shown that trans fats (produced during the processing of vegetable oils) and saturated fatty acids (SFAs) are linked to a higher risk of type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease, which is characterized by the buildup of liver fat, insulin resistance, and metabolic syndrome. Therefore, consuming fewer saturated fats (SFAs) and more monounsaturated and polyunsaturated fats is advised to promote well-being acids (PUFAs) [47].

Through transcription factors' direct and indirect activation, dietary lipids control gene expression, affecting inflammation, endothelial functions, metabolism, and cell development and differentiation. This is the situation with polyunsaturated fats (PUFAs), which comprise the  $\omega$ -3 and  $\omega$ -6 families of PUFAs respectively. PUFAs, in particular, act as fuel partitioners, directing fatty acids away from triglyceride synthesis and absorption, towards  $\beta$ -oxidation and glucose towards glycogen storage. Table 1 illustrates how PUFAs, in particular N-3 PUFAs, stimulate the transcription of genes encoding enzymes for  $\beta$ -oxidation and thermogenesis while suppressing the transcription of lipogenic genes. Furthermore, the expression of genes linked to adipocyte development is downregulated by  $\omega$ -3 PUFAs and upregulated by  $\omega$ -6 PUFAs [48].



**Figure 3.** Phosphorylates Ser568 to block ChREBP DNA-binding ability.



**Figure 4.** Cholesterol and unsaturated fatty acids activate SREBPs by proteolysis. Refer to the text for further details. HMG-CoA, 5-hydroxy-3-methylglutaryl-coenzyme A; INSIG, insulin-induced protein; LDLR, low-density lipoprotein receptor; ER, endoplasmic reticulum; FAS, fatty acid synthase; bHLH stands for basic helix-loop-helix domain; ACS stands for acetyl-CoA synthetase; PCSK9, proprotein convertase subtilisin/kexin type 9; Reg, regulatory domain; SP1, site-1 protease; SP2, site-2 protease; SCAP, SREBP cleavage-activating protein; Sterol-responsive elements are referred to as SREs, and the protein that binds to these elements is known as SREBP.

Fatty acids directly bind liver X receptors (LXRs) and PPARs to produce these effects. In addition, they indirectly influence the activity of other nuclear factors, such as nuclear factor kappa B (NF $\kappa$ B), SREBPs, and hepatocyte nuclear factor 4 $\alpha$  (HNF4 $\alpha$ ). We outline the primary features of these receptors here, with references to additional articles for more information.

#### Regulation of transcription factors and their relationship to dietary fat.

Via the modulation of their regulatory pathways, fatty acids, particularly polyunsaturated fats (PUFAs), can control the quantity of certain transcription factors within the nucleus. This is an example of how both  $\omega$ -3 and  $\omega$ -6 PUFAs antagonistically activate the activator protein (AP)-1 transcription factor through a method that depends on PKC- $\alpha$  activation. For example, a diet high in  $\omega$ -6 PUFAs stimulates PKC $\beta$ II activity, normally controlled by  $\omega$ -3 PUFAs, increasing colon cancer cell proliferation [49].

All three SREBPs have a central region with two hydrophobic transmembrane segments facing into the endoplasmic reticulum (ER) lumen, an N-terminal bHLH/ZIPDNA-binding domain, and a C-terminal regulatory domain that is found in the cytosol and is essential for SREBP maturation. Their susceptibilities to insulin, PUFAs, and cholesterol control vary, although having the same structure (Figure 4) [21].

#### Genetic changes and their relationship to protein nutrition.

Given the abundance of information available on protein genomics (and the nutrigenomics of micronutrients; refer to the following paragraph), a select few noteworthy instances will be discussed to illustrate the intricate web that underlies the health benefits of these nutrients [51,52].

The synthesis of cholesterol is one of the metabolic processes that dietary proteins control. Indeed, a substantial hypocholesterolemic effect (a decrease in blood total and LDL-cholesterol concentrations) is observed in proteins, particularly soy proteins, probably due to SREBP-2 regulation. As a result, giving a low-protein meal causes insulin levels to drop. It decreases the mass of pancreatic  $\beta$ -cells. Specifically, protein restriction hinders the function of both calcium- and cAMP-dependent PKC and PKA, which work together to cause the transcription of genes needed for insulin synthesis, glucose sensing, exocytosis, and  $\beta$ -cell survival that is dependent on the response element-binding (CREB) protein [53,54].

#### Genetic changes and their relationship to nutrients.

Minerals and vitamins are necessary nutrients that directly impact biochemical processes and can control gene expression. They enhance health by altering certain signal transduction pathways directly through interactions with transcription factors (such as vitamins A and D) or indirectly through epigenetic alterations of target promoters.

All-trans and 9-cis retinoic acid, metabolites of vitamin A, have various pleiotropic effects, including differentiation, cell death, proliferation, and metabolism. They are very important for developing embryos and fetuses and preserving the completely differentiated condition of adults. Binding to two kinds of nuclear receptors—retinoic acid, and retinoid-X, receptors—is necessary for retinoids to function. These receptors form heterodimers and bind to retinoic acid response elements (RAREs) on target gene loci [55].

Comparably, most of vitamin D's physiological effects come from attaching to the vitamin D receptor, which controls over 1000 genes throughout all tissues. However, vitamin D also causes epigenetic changes, including hypomethylation, which activates the osteocalcin promoter. By altering the redox status of transcription factors and signaling molecules, antioxidant vitamins C and E have been demonstrated to influence the production of extracellular matrix components and proteins involved in advancing the cell cycle.

Nutrients involved in one-carbon metabolism provide another interesting example. Epigenetic patterns can be modified by vitamins, certain amino acids, and certain minerals by varying the amounts of the methyl donor S-adenosylmethionine, which is required for DNA methylation and histone modifications [56,57].

#### Conclusion.

There is no denying that research on dietary genetics and its application to preventing and treating cardiovascular illnesses is still in its early stages. However, obtaining consistent results was greatly aided by introducing more productive (and less expensive) technologies and the increasing number of intervention studies, which included nutritional analysis. Co-

applying additional "omics" disciplines, such as transcriptomics, proteomics, metabolomics, nutritional genomics, genomes, and lipidomics, can further improve this encouraging situation. The capacity to effectively apply an integrated modeling strategy, incorporating phenotypic, genetic, and epigenetic data from the Framingham Heart research, to simulate the symptoms of coronary heart disease. This is an all-encompassing strategy for making customized drugs and diets a reality, particularly in preventing obesity and cardiovascular disease.

### Acknowledgments.

**Authors' contributions:** All authors of the manuscript collected the data, reviewed it, studied the Medical statistical analysis, and wrote the manuscript. The authors also declare that they have approved the manuscript and approved its content.

**Funding:** No funding to declare.

**Data and materials:** The respective authors will provide the datasets used in this study upon request.

**Declarations:** The College of Pharmacy's Ethical Committee permitted the study to proceed in some health locations. The authors declare no competing interests.

### REFERENCES

- Karczewski J, Sledzinska E, Baturo A, et al. Obesity and inflammation. *Eur Cytokine Netw.* 2018;29:83-94.
- Goodarzi MO. Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. *Lancet.* 2018;6:223-36.
- Webb TR, Erdmann J, Stirrups KE, et al. Systematic evaluation of pleiotropy identifies 6 further loci associated with coronary artery disease. *J Am Coll Cardiol.* 2017;69:823-36.
- Vazquez-Vidal I, Desmarchelier C, Jones PJH. Nutrigenetics of blood cholesterol concentrations: towards personalized nutrition. *Curr Cardiol Rep.* 2019;21:38.
- Elsamanoudy AZ, Mohamed Neamat-Allah MA, Hisham Mohammad FA, et al. The role of nutrition related genes and nutrigenetics in understanding the pathogenesis of cancer. *J Microsc Ultrastruct.* 2016;4:115-22.
- Xu M, Zhao J, Zhang Y, et al. Apolipoprotein E gene variants and risk of coronary heart disease: a meta-analysis. *BioMed Res Int.* 2016;2016:3912175.
- Roncero-Ramos I, Rangel-Zuniga OA, Lopez-Moreno J, et al. Mediterranean diet, glucose homeostasis, and inflammasome genetic variants: The CORDIOPREV Study. *Mol Nutr Food Res.* 2018;62:e1700960.
- de Toro-Martin J, Arsenault BJ, Despres JP, et al. Precision nutrition: a review of personalized nutritional approaches for the prevention and management of metabolic syndrome. *Nutrients.* 2017;9:913-41.
- Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. *Metabolism.* 2019;92:98-107.
- Guglielmi V, Sbraccia P. Epicardial adipose tissue: at the heart of the obesity complications. *Acta Diabetol.* 2017;54:805-12.
- Li XS, Obeid S, Klingenberg R, et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. *Eur Heart J.* 2017;38:814-24.
- Randrianarisoa E, Lehn-Stefan A, Wang X, et al. Relationship of serum trimethylamine noxide (TMAO) levels with early atherosclerosis in humans. *Sci Rep.* 2016;6:26745.
- Haghikia A, Li XS, Liman TG, et al. Gut microbiota-dependent trimethylamine Noxide predicts risk of cardiovascular events in patients with stroke and is related to proinflammatory monocytes. *Arterioscler Thromb Vasc Biol.* 2018;38:2225-35.
- Ross LJ, Barnes KA, Ball LE, et al. Effectiveness of dietetic consultation for lowering blood lipid levels in the management of cardiovascular disease risk: A systematic review and meta-analysis of randomised controlled trials. *Nutr Diet.* 2019;76:199-210.
- Reddy VS, Palika R, Ismail A, et al. Nutrigenomics: opportunities & challenges for public health nutrition. *Indian J Med Res.* 2018;148:632-41.
- Derosa G, Sahebkar A, Maffioli P. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. *Journal of Cell Physiology. J Cell Physiol.* 2018;233:153-161.
- Drag J, Go'zdzińska A, Knapik-Czajka M, et al. Effect of high carbohydrate diet on elongase and desaturase activity and accompanying gene expression in rat's liver. *Genes Nutrition.* 2017;12:2.
- Komati R, Spadoni D, Zheng S, et al. Ligands of therapeutic utility for the liver x receptors. *Molecules.* 2017;22:E88.
- Toral M, Romero M, Pérez-Vizcaíno F, et al. Antihypertensive effects of peroxisome proliferator-activated receptor- $\beta/\delta$  activation. *American Journal of Physiology. Heart and Circulatory Physiology.* 2017;312:H189-H200.
- Barrea L, Annunziata G, Bordoni L, et al. Nutrigenetics—personalized nutrition in obesity and cardiovascular Diseases. *International Journal of Obesity Supplements.* 2020;10:1-13.
- Gasperi V, Vangapandu C, Catani MV, et al. *Nutrigenomics.* Wiley & Sons. Ltd: Chichester. 2017.
- Wang B, Yang Q, Harris CL, et al. Nutrigenomic regulation of adipose tissue development – role of retinoic acid: a review. *Meat Science.* 2016;120:100-106.
- Colle R, de Larminat D, Rotenberg S, et al. PPAR- $\gamma$  agonists for the treatment of major depression: a review. *Pharmacopsychiatry.* 2017;50:49-55.
- Herman MA, Samuel VT. The sweet path to metabolic demise: fructose and lipid synthesis. *Trends in Endocrinology & Metabolism.* 2016;27:719-730.
- Ma Z, Deng C, Hu W, et al. Liver X receptors and their agonists: targeting for cholesterol homeostasis and cardiovascular diseases. *Current Issues in Molecular Biology.* 2017;22:41-64.
- Moon YA. The SCAP/SREBP pathway: a mediator of hepatic steatosis. *Endocrinology and Metabolism.* 2017;32:6-10.
- Paniagua JA. Nutrition, insulin resistance and dysfunctional adipose tissue determine the different components of metabolic syndrome. *World Journal of Diabetes.* 2016;7:483-514.
- Savini I, Catani MV, Evangelista D, et al. Obesity-associated oxidative stress: strategies finalized to improve redox state. *International Journal of Molecular Science.* 2013;14:10497-10538.

29. Sciacca S, Conti G. Mutagens and carcinogens in drinking water. *Mediterranean Journal of Nutrition and Metabolism*. 2009;2:157-162.
30. Ellis L, Atadja P, Johnstone R. Epigenetics in cancer: Targeting chromatin modifications. *Molecular Cancer Therapy*. 2009;8:1409-1420.
31. Sjaastad A, Svendsen K. Exposure to polycyclic aromatic hydrocarbons (PAHs), mutagenic aldehydes, and particulate matter in Norwegian A la carte restaurants. *Annals of Occupational Hygiene*. 2009;53:723-729.
32. Ruthenburg A, Li H, Patel D, et al. Multivalent engagement of chromatin modifications by linked binding modules. *Nature Review Molecular Cell Biology*. 2007;8:983-994.
33. Pal S, Ola S, John R. Epigenetics and MicroRNAs. *Pediatric Research*. 2007;61:17R-23R.
34. Paniagua JA. Nutrition, insulin resistance and dysfunctional adipose tissue determine the different components of metabolic syndrome. *World Journal of Diabetes*. 2016;7:483-514.
35. Savini I, Catani MV, Evangelista D, et al. Obesity-associated oxidative stress: strategies finalized to improve redox state. *International Journal of Molecular Science*. 2013;14:10497-10538.
36. Iizuka K. The role of carbohydrate response element binding protein in intestinal and hepatic fructose metabolism. *Nutrients*. 2017;9:E181.
37. Takeuchi Y, Yahagi N, Izumida Y, et al. Polyunsaturated fatty acids selectively suppress sterol regulatory element-binding protein-1 through proteolytic processing and autoloop regulatory circuit. *Journal of Biology Chemistry*. 2010;285:11681-11691.
38. Pagliaro B, Santolamazza C, Simonelli F, et al. Phytochemical compounds and protection from cardiovascular diseases: a state of the art. *BioMed Research International*. 2015:918069.
39. de Luis DA, Izaola O, de la Fuente B, et al. Polymorphism of neuropeptide Y gene rs16147 modifies the response to a hypocaloric diet on cardiovascular risk biomarkers and adipokines. *J Hum Nutr Diet*. 2017;30:159-65.
40. Neyestani TR, Djazayeri A, Shab-Bidar S, et al. Vitamin D receptor Fok-I polymorphism modulates diabetic host response to vitamin D intake: need for a nutrigenetic approach. *Diabetes Care*. 2013;36:550-6.
41. Annunziata G, Maisto M, Schisano C, et al. Effects of grape pomace polyphenolic extract (Taurisol(R)) in reducing TMAO serum levels in humans: preliminary results from a randomized, placebo-controlled, cross-over study. *Nutrients*. 2019;11:139-50.
42. Shunmoogam N, Naidoo P, Chilton R. Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. *Vasc Health Risk Manag*. 2018;14:137-43.
43. Montserrat Fitó, Valentini Konstantinidou. Nutritional Genomics and the Mediterranean Diet's Effects on Human Cardiovascular Health, *Nutrients*. 2016;8:218.
44. Scoditti E, Capurso C, Capurso A, et al. Vascular effects of the Mediterranean diet-part II: Role of omega-3 fatty acids and olive oil polyphenols. *Vascul. Pharmacol*. 2014;63:127-134.
45. Konstantinidou V, Ruiz L.A, Ordoñas J.M. Personalized nutrition and cardiovascular disease prevention: From Framingham to PREDIMED. *Adv. Nutr*. 2014;5:368S-371S.
46. Donini L.M, Serra-Majem L, Bulló M, et al. The Mediterranean diet: Culture, health and science. *Br. J. Nutr*. 2015;113:S1-S3.
47. Ros E, Martínez-González M.A, Estruch R, et al. Mediterranean diet and cardiovascular health: Teachings of the PREDIMED study. *Adv. Nutr*. 2014;5:330S-336S.
48. Corella D, Jose M. Ordoñas. Nutrigenomics in Cardiovascular Medicine. *Circ Cardiovasc Genet*. 2009;2:637-651.
49. O'Donnell CJ, Nabel EG. Cardiovascular Genomics, Personalized Medicine, and the National Heart, Lung, and Blood Institute: Part I: The Beginning of an Era. *Circ Cardiovasc Genet*. 2008;1:51-57.
50. Ioannidis JPA. Prediction of Cardiovascular Disease Outcomes and Established Cardiovascular Risk Factors by Genome-Wide Association Markers. *Circ Cardiovasc Genet*. 2009;2:7-15.
51. Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. *Nat Rev Genet*. 2009;10:109-121.
52. Mentz A, de Koning L, Shannon HS, et al. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. *Arch Intern Med*. 2009;169:659-669.
53. Whitfield-Brown L, Hamer O, Ellahi B, et al. An investigation to determine the nutritional adequacy and individuals experience of a very low-fat diet used to treat type V hypertriglyceridaemia. *J Hum Nutr Diet*. 2009;22:232-238.
54. Brown JM, Shelness GS, Rudel LL. Monounsaturated fatty acids and atherosclerosis: opposing views from epidemiology and experimental animal models. *Curr Atheroscler Rep*. 2007;9:494-500.
55. Russo GL. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. *Biochem Pharmacol*. 2009;77:937-946.
56. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *N Engl J Med*. 2009;360:859-873.
57. Lovegrove JA, Gitau R. Personalized nutrition for the prevention of cardiovascular disease: a future perspective. *J Hum Nutr Diet*. 2008;21:306-316.